403 related articles for article (PubMed ID: 12490973)
1. Loss of heterozygosity of p53, BRCA1, VHL, and estrogen receptor genes in breast carcinoma: correlation with related protein products and morphologic features.
Otis CN; Krebs PA; Albuquerque A; Quezado MM; San Juan X; Sobel ME; Merino MJ
Int J Surg Pathol; 2002 Oct; 10(4):237-45. PubMed ID: 12490973
[TBL] [Abstract][Full Text] [Related]
2. Loss of heterozygosity in P53, BRCA1, and estrogen receptor genes and correlation to expression of p53 protein in ovarian epithelial tumors of different cell types and biological behavior.
Otis CN; Krebs PA; Quezado MM; Albuquerque A; Bryant B; San Juan X; Kleiner D; Sobel ME; Merino MJ
Hum Pathol; 2000 Feb; 31(2):233-8. PubMed ID: 10685639
[TBL] [Abstract][Full Text] [Related]
3. Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in young women.
Querzoli P; Albonico G; di Iasio MG; Ferretti S; Rinaldi R; Cariello A; Pedriali M; Matteuzzi M; Maestri I; Nenci I
Breast Cancer Res Treat; 2001 Mar; 66(2):135-42. PubMed ID: 11437099
[TBL] [Abstract][Full Text] [Related]
4. Loss of heterozygosity in BRCA1 and BRCA2 markers and high-grade malignancy in breast cancer.
Silva JM; Gonzalez R; Provencio M; Dominguez G; Garcia JM; Gallego I; Palacios J; España P; Bonilla F
Breast Cancer Res Treat; 1999 Jan; 53(1):9-17. PubMed ID: 10206068
[TBL] [Abstract][Full Text] [Related]
5. Frequent loss of heterozygosity on chromosomes 3p and 17p without VHL or p53 mutations suggests involvement of unidentified tumor suppressor genes in follicular thyroid carcinoma.
Grebe SK; McIver B; Hay ID; Wu PS; Maciel LM; Drabkin HA; Goellner JR; Grant CS; Jenkins RB; Eberhardt NL
J Clin Endocrinol Metab; 1997 Nov; 82(11):3684-91. PubMed ID: 9360526
[TBL] [Abstract][Full Text] [Related]
6. [Loss of heterozygosity of tumor suppressor genes at chromosome 3p in transitional cell carcinoma of urinary bladder].
Xiao Z; Zhang J; Zheng S; Li C; He Z; Cheng S; Gao Y
Zhonghua Yi Xue Za Zhi; 2002 Oct; 82(20):1375-7. PubMed ID: 12509916
[TBL] [Abstract][Full Text] [Related]
7. Microsatellite alterations on human chromosome 11 in in situ and invasive breast cancer: a microdissection microsatellite analysis and correlation with p53, ER (estrogen receptor), and PR (progesterone receptor) protein immunoreactivity.
Shen KL; Yang LS; Hsieh HF; Chen CJ; Yu JC; Tsai NM; Harn HJ
J Surg Oncol; 2000 Jun; 74(2):100-7. PubMed ID: 10914818
[TBL] [Abstract][Full Text] [Related]
8. Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53.
Werness BA; Parvatiyar P; Ramus SJ; Whittemore AS; Garlinghouse-Jones K; Oakley-Girvan I; DiCioccio RA; Wiest J; Tsukada Y; Ponder BA; Piver MS
J Natl Cancer Inst; 2000 Jul; 92(13):1088-91. PubMed ID: 10880552
[TBL] [Abstract][Full Text] [Related]
9. Loss of heterozygosity of BRCA1, TP53 and TCRD markers analysed in sporadic endometrial cancer.
Niederacher D; An HX; Camrath S; Dominik SI; Göhring UJ; Oertel A; Grass M; Hantschmann P; Lordnejad MR; Beckmann MW
Eur J Cancer; 1998 Oct; 34(11):1770-6. PubMed ID: 9893667
[TBL] [Abstract][Full Text] [Related]
10. Sporadic breast carcinomas with somatic BRCA1 gene deletions share genotype/phenotype features with familial breast carcinomas.
Rhiem K; Todt U; Wappenschmidt B; Klein A; Wardelmann E; Schmutzler RK
Anticancer Res; 2010 Sep; 30(9):3445-9. PubMed ID: 20944121
[TBL] [Abstract][Full Text] [Related]
11. Loss of heterozygosity is detected at chromosomes 1p35-36 (NB), 3p25 (VHL), 16p13 (TSC2/PKD1), and 17p13 (TP53) in microdissected apocrine carcinomas of the breast.
Lininger RA; Zhuang Z; Man Y; Park WS; Emmert-Buck M; Tavassoli FA
Mod Pathol; 1999 Dec; 12(12):1083-9. PubMed ID: 10619258
[TBL] [Abstract][Full Text] [Related]
12. Loss of heterozygosity of the von Hippel Lindau gene locus in polypoid dysplasia but not flat dysplasia in ulcerative colitis or sporadic adenomas.
Fogt F; Vortmeyer AO; Stolte M; Mueller E; Mueller J; Noffsinger A; Poremba C; Zhuang Z
Hum Pathol; 1998 Sep; 29(9):961-4. PubMed ID: 9744312
[TBL] [Abstract][Full Text] [Related]
13. Loss of heterozygosity of the VHL gene identifies malignancy and predicts death in follicular thyroid tumors.
Hunt JL; Yim JH; Tometsko M; Finkelstein SD; Swalsky P; Carty SE
Surgery; 2003 Dec; 134(6):1043-7; discussion 1047-8. PubMed ID: 14668739
[TBL] [Abstract][Full Text] [Related]
14. Loss of heterozygosity of BRCA1, BRCA2 and ATM genes in sporadic invasive ductal breast carcinoma.
Rio PG; Pernin D; Bay JO; Albuisson E; Kwiatkowski F; De Latour M; Bernard-Gallon DJ; Bignon YJ
Int J Oncol; 1998 Oct; 13(4):849-53. PubMed ID: 9735416
[TBL] [Abstract][Full Text] [Related]
15. Association between loss of heterozygosity of BRCA1 and BRCA2 and morphological attributes of sporadic breast cancer.
Hanby AM; Kelsell DP; Potts HW; Gillett CE; Bishop DT; Spurr NK; Barnes DM
Int J Cancer; 2000 Oct; 88(2):204-8. PubMed ID: 11004669
[TBL] [Abstract][Full Text] [Related]
16. Molecular genetic analysis of the von Hippel-Lindau and human peroxisome proliferator-activated receptor gamma tumor-suppressor genes in adenocarcinomas of the gastroesophageal junction.
Wijnhoven BP; Lindstedt EW; Abbou M; Ijzendoorn Y; de Krijger RR; Tilanus HW; Dinjens WN;
Int J Cancer; 2001 Dec; 94(6):891-5. PubMed ID: 11745495
[TBL] [Abstract][Full Text] [Related]
17. Loss of heterozygosity on chromosome 1 and 9 and hormone receptor analysis of metastatic malignant melanoma presenting in breast.
Beaty MW; Quezado M; Sobel ME; Duray P; Merino MJ
Int J Surg Pathol; 2005 Jan; 13(1):9-18. PubMed ID: 15735850
[TBL] [Abstract][Full Text] [Related]
18. Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC).
Singh RB; Amare Kadam PS
Urol Oncol; 2013 Oct; 31(7):1333-42. PubMed ID: 21962529
[TBL] [Abstract][Full Text] [Related]
19. Loss of heterozygosity at 17p13.3-ter, distal to TP53, correlates with negative hormonal phenotype in sporadic breast cancer.
Roncuzzi L; Brognara I; Baiocchi D; Amadori D; Gasperi-Campani A
Oncol Rep; 2005 Aug; 14(2):471-4. PubMed ID: 16012732
[TBL] [Abstract][Full Text] [Related]
20. Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors.
Sourvinos G; Spandidos DA
Biochem Biophys Res Commun; 1998 Apr; 245(1):75-80. PubMed ID: 9535786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
